[{"id":"1e5fae6d-b76f-41f6-b24b-b33b5b08e9ca","acronym":"ORIC-114-01","url":"https://clinicaltrials.gov/study/NCT05315700","created_at":"2022-04-07T13:56:31.880Z","updated_at":"2024-07-02T16:35:04.393Z","phase":"Phase 1/2","brief_title":"Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration","source_id_and_acronym":"NCT05315700 - ORIC-114-01","lead_sponsor":"ORIC Pharmaceuticals","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • HER-2 amplification • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 exon 23 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • HER-2 amplification • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • enozertinib (ORIC-114)"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-05-10"}]